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TP508 is a 23-amino acid peptide derived from human prothrombin that increases cartilage matrix production and reduces alkaline phosphatase
activity without changing chondrocyte proliferation. This study tested the hypothesis that TP508 acts by blocking the onset of apoptosis associated
with hypertrophy. Rat costochondral resting zone chondrocytes and human auricular chondrocytes were cultured in DMEM containing 50μM
ascorbic acid and 10% FBS. Apoptosis was induced by treatment of confluent cultures with chelerythrine, tamoxifen, or inorganic phosphate (Pi)
for 24h. One half of the cultures received TP508 (0, 0.7, or 7μg/ml). Apoptosis was assessed as a function of DNA fragmentation ([3H]-thymidine
labeled DNA fragments), TUNEL staining, and cell viability using the MTT assay, as well as by assessing the Bcl-2/Bax mRNA and protein ratios
and caspase-3 activity. The universal NO synthase inhibitor L-NMMAwas used to assess the effect of NO production on chondrocyte apoptosis
and specific NO synthase subspecies were identified using iNOS inhibitor 1400W and nNOS inhibitor vinyl-L-NIO, as well as L-NAME, which
inhibits both iNOS and eNOS. Finally, we assessed if TP508 would block NO production induced by the apoptogens. Chelerythrine, tamoxifen
and Pi-induced apoptosis and this was reversed by TP508. All apoptogens increased NO production and this was reduced by TP508. TP508
reduced NO levels to the same extent as 1400W but not to the same extent as L-NAME, suggesting that its effects are mediated primarily by iNOS.
In addition, TP508 reduced the effect of chelerythrine to the same extent as 1400W and L-NAME, again indicating that it acts via inhibition of an
iNOS pathway. TP508 also regulated Bcl-2/Bax mRNA in a time and dose-dependent manner. The Bcl-2/Bax mRNA ratio was 0.11 in the
absence of TP508 at 1h and 4.95 at 7μg/ml TP508; by 3h the ratio was approximately 1 in both groups. The Bcl-2/Bax protein ratio also increased
by 63% at 1h. TP508 did not affect caspase-3 activity. TP508 also caused a dose-dependent increase in protein kinase C (PKC) activity within
9min that was maximal at 270min. These results show that TP508 prevents apoptosis in growth plate chondrocytes via inhibition of iNOS-
dependent NO and suggest a possible role for PKC in the mechanism.
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Bone repair occurs via endochondral bone formation around
a fracture site. Its efficiency depends on the balance between
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doi:10.1016/j.bbamcr.2007.10.009tilage template preceding bone formation, all of which are
regulated by multiple systemic and local regulators. The process
of bone repair recapitulates the events that occur during
embryonic bone formation and in many respects, the events
that occur during post-natal long bone growth [1,2]. During
long bone growth, cells in the resting zone, which are embedded
in an extracellular matrix rich in type II collagen and pro-
teoglycan aggregates containing sulfated glycosaminoglycans,
are induced to proliferate, followed by a shift in phenotype
to a hypertrophic cell that ultimately calcifies its extracellular
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plate routinely undergo physiological apoptosis, especially during
terminal differentiation [3–6], and studies indicate that elevated
extracellular phosphate and nitric oxide (NO) production are
involved [7,8].
Apoptosis in the resting zone occurs less frequently [9]. It is
not known whether it is induced by pathways that act in the
hypertrophic zone or if factors exist that can rescue resting zone
cells from apoptosis once it has been induced. To better under-
stand the mechanisms involved in regulation of apoptosis in
these cells, we took advantage of recent observations concerning
thrombin peptide TP508 (Chrysalin®, OrthoLogic Corp, Tempe,
AZ). TP508 is a 23-amino acid peptide representing the human
thrombin amino acid sequence originally identified as the
receptor binding domain responsible for thrombin binding and
activation of a high-affinity class of receptors on fibroblasts [10].
It has been shown to accelerate fracture repair in a rat closed
diaphyseal fracture model, which heals through an endochondral
process [1,11]. One effect of the peptide was to increase the
callus mass, a tissue that consists of proliferating and prehyper-
trophic chondrocytes. Ultimately, cells in the callus undergo
hypertrophy and calcify their matrix, leading to vascular inva-
sion and bone formation.
The purpose of the callus is to stabilize the bony ends of the
fracture so agents that cause this to happen more rapidly are
likely to affect cells at early stages of endochondral maturation.
Studies using rat costochondral growth plate chondrocytes,
which are similar to the prehypertrophic cells in the fracture
callus, support this hypothesis [12]. These cells were differen-
tially affected by TP508 in a manner that promoted prolonga-
tion of the chondrocytic lineage. Although TP508 had no effect
on proliferation, it stimulated production of sulfated glycosa-
minoglycans, a hallmark of cartilage extracellular matrix, and it
inhibited growth plate chondrocyte maturation based on de-
creased alkaline phosphatase activity. Increased alkaline
phosphatase is associated with chondrocyte hypertrophy and
apoptosis [13,14]. Therefore, it is important to elucidate
whether TP508 is able to block chondrocyte apoptosis, and if
so, its mechanism of action.
The apoptotic pathway in growth plate chondrocytes can be
activated by high concentrations of inorganic phosphate (Pi) [7],
and is mediated through signals that include a rapid increase in
nitric oxide [8]. Chick sternal chondrocytes possess inducible
nitric oxide synthase (iNOS), neuronal NOS (nNOS), and
endothelial NOS (eNOS) and treatment of the cells with NOS
inhibitors decreases alkaline phosphatase [15]. This suggests
that peptides like TP508, which reduce alkaline phosphatase,
may also act as anti-apoptotic agents via a mechanism that
involves reduction in NO. To determine if TP508 can prevent
apoptosis in these cells, we first examined whether TP508
regulates expression of Bcl-2 or Bax, since previous studies
have shown that an increase in the Bcl-2/Bax ratio favors
protection against apoptosis [16,17]. In addition, we assessed
the effects of TP508 on protein kinase C (PKC) activity since
activation of this enzyme has been associated with cell
proliferation in other systems [18–20]. Apoptosis was induced
by treating confluent cultures with three different apoptoticagents. Whether TP508 could reverse their ability to stimulate
NO production or apoptosis was determined.
2. Materials and methods
2.1. Materials
The 23-amino acid synthetic thrombin peptide TP508, also known as
Chrysalin®, comprising amino acids 508–530 of human prothrombin
(AGYKPDEGKRGDACEGDSGGPFV, mol wt of 2311.5) synthesized by
Bachem California (Torrance, CA), was provided for these studies by
OrthoLogic Corp. (Tempe, AZ). The peptide was shown by HPLC to be
greater than 97% pure. It was stored as a lyophilized powder and reconstituted
with medium prior to addition to cells.
2.2. Cell culture
Chondrocytes were isolated from the resting zone of the costochondral
cartilage of 125-g Sprague–Dawley rats, as described previously [21]. Initial
experiments compared cells from male and female donors to rule out any sex-
specific differences in mechanism. At third passage confluence, the chondro-
cytes were subpassaged into 24-well plates such that there were six separate
cultures per variable per experiment. TP508 was dissolved in culture media and
then added to the cultures at concentrations of 0.07, 0.7 and 7.0μg/ml. Previous
studies validated the specificity of the response of chondrocytes to TP508 by
using a scrambled peptide containing the same amino acids as TP508, but in a
different order (AVDPEGRAGCGGDPKYGDFSKEG) [12].
To determine if TP508 also had effects on human cartilage cells, human
auricular chondrocytes were used. Human cartilage was obtained via an IRB-
approved protocol, cleaned of adjacent connective tissue, minced and washed
with 10ml Hank's Balanced Salt Solution (Invitrogen, Carlsbad, CA) containing
10% penicillin/streptomycin (Mediatech, Herndon, VA) twice for 20min.
Following treatment with 5ml 0.25% trypsin–1mM EDTA (Invitrogen) for 1h,
the samples were treated for 6h with 12.5ml 0.2% collagenase type II
(Worthington Biochem, Lakewood, NJ) containing 1% penicillin/streptomycin.
The collagenase treated samples were sieved through a cell strainer (BD
Biosciences, San Jose, CA), collected in a 50ml centrifuge tube, and centrifuged
at 2000rpm for 10min. The supernatant was removed, and the pellet was
suspended in 10ml media containing 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin (Mediatech, Herndon, VA) and 1% ascorbic acid
(Sigma-Aldrich, St. Louis, MO). After determining cell yield using a Beckman
Coulter Z1 Cell Counter (Beckman Coulter, Fullerton, CA), the cells were plated
in 24-well plates at a density of 10,000cells/cm2.
2.3. Regulation of Bcl-2 and Bax
Effects of TP508 on Bcl-2 and Bax expression were assessed by RT-PCR of
RNA isolated from female resting zone chondrocytes that were treated with 0,
0.07, 0.7 or 7μg/ml TP508 for 1, 3, 6 and 12h. RNAwas isolated after lysis of the
cells with TRIzol (Invitrogen, Carlsbad, CA). Total RNAwas reverse-transcribed
using specific primers described below and the Omniscript RT kit fromQIAGEN
(Valencia, CA). Following the initial reverse transcription reaction, the cDNA
was amplified using a polychain amplification reaction (PCR) by adding a pair of
specific primers and Taq DNA polymerase (Fisher Scientific, Hampton, NH).
The PCR products were separated by electrophoresis and measured semi-
quantitatively by densitometry using VersaDoc Imaging System (Bio-Rad,
Hercules, CA). Primer sequences were designed using Beacon Designer 5
(Premier Biosoft International, Palo Alto, CA) according to the published
sequence of rat Bcl-2 (GenBank accession number L14680) and Bax (GenBank
accession number AF235993) mRNA. The primers used in this study are: Bcl-2
sense primer, 5′-CTCCTGGCTGTCTCTGAAG-3′ and antisense primer, 5′-
TCTGCTGACCTCACTTGTG-3′; Bax sense primer, 5′-CCATCAGAAGCAG-
TAGCC-3′ and antisense primer, 5′-TGGAGAGAGGAGGAAAGG-3′. The
expected product sizes were 95 base pairs (Bcl-2) and 134 base pairs (Bax).
Effects on Bcl-2 and Bax protein levels were determined by Western blot of
cell culture lysates prepared from female rat resting zone chondrocytes.
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of the gels were probed with mouse monoclonal antibodies to Bcl-2 (cat#
610539, purified mouse anti-Bcl-2, BD Biosciences, Franklyn Lakes, NJ) and
Bax (sc-7480, Bax(B9), Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Two other antibodies against Bcl-2 [sc-7382, Bcl-2(C-2) and sc-783, Bcl-2(DC
21) (Santa Cruz Biotechnology)], and two other antibodies against Bax [sc-
6236, Bax(δ21) (Santa Cruz Biotechnology) and a purified mouse anti-Bax
monoclonal antibody (cat#556467, BD Biosciences)] were also tested, but no
positive bands were obtained. Immunoreactive bands were detected using
1:5000 dilutions of horseradish peroxidase-conjugated goat anti-mouse IgG
(Santa Cruz Biotechnology), and visualized using enhanced chemilumines-
cence (ECL; Amersham Biosciences, Piscataway, NJ). Controls were
performed with anti-GAPDH antibodies (Mab374, Chemicon International,
Temecula, CA). Immunoreactive bands were scanned and their relative
intensities determined.
2.4. Protein kinase C activity
PKC specific activity was determined in cell layer lysates as a function of
dose and time using an assay kit (Protein Kinase C Enzyme Biotrak AssayFig. 1. Panel A: Effect of TP508 on Bcl-2 and Bax expression in rat costochondral
TP508 for 1, 3, 6, and 12 h. Relative levels of each mRNAwere determined by dens
lysates were separated by SDS-PAGE and Bcl-2 and Bax detected byWestern blot. Da
of TP508 on PKC specific activity. Cultures were treated with 0.7 to 14 μg/ml TP50
presented are from one of at least two separate experiments, all of which had comp
TP508 v. all other treatments at 270 min.System, Amersham Biosciences, Buckinghamshire, England), as previously
described [22]. NO production was determined using a 2,3-diaminonaphthlene-
based assay (DAN) of the conditioned media as described by Misko et al. [23].
2.5. Apoptosis assays
Apoptosis was induced using three different methods. Confluent cultures of
resting zone chondrocytes were treated for 24h with chelerythrine (0.1, 1, or
10μM), which has been shown to induce apoptosis in leukocytes, cardiac
myocytes and some cancer cells [24–26] or tamoxifen (10− 10, 10− 9, or 10− 8M),
which has been shown to induce apoptosis in multiple human cancer cells [27–
29]. Both of these agents inhibit PKC in resting zone cells in a dose-dependent
manner [30,31]. In addition, we tested the effects of 10μM chelerythrine and 10−
9M tamoxifen in combination. Alternatively, confluent cultures were treated for
24h with Pi (0, 2.5, 5, and 7.5mM), which has been shown to induce apoptosis in
chick growth plate chondrocytes [7]. To determine if TP508 could block the
apoptotic effects of these agents, cultures were treated with 10μM chelerythrine,
10− 9M tamoxifen, or 7.5mM Pi; one half of the cultures also received TP508 (0,
0.7 or 7μg/ml). Similarly, human auricular chondrocytes were treated with
control media or 10μM chelerythrine with and without 7μg/ml TP508.resting zone chondrocytes. Cultures were treated with 0, 0.07, 0.7 and 7 μg/ml
itometry. Panel B: Effect of TP508 on Bcl-2 and Bax protein levels. Cell culture
ta are from one of three experiments, all with comparable results. Panel C: Effect
8 for 9 to 720 min. Data are means±SEM for N=6 independent cultures. Data
arable results. ⁎Pb0.05, treatment v. vehicle at each time; #Pb0.05, 0.7 μg/ml
Fig. 2. Effect of TP508 on cell number (A), cell viability (B) and DNA
fragmentation (C) of confluent resting zone costochondral growth plate
chondrocyte cultures isolated from female rats. Cultures were treated with 0,
0.7 or 7 μg/ml for 24 h in the presence or absence of 10 μM chelerythrine. Data
are means±SEM for N=6 independent cultures. Data presented are from one of
at least two separate experiments, all of which had comparable results. ⁎Pb0.05,
TP508 treatment v. vehicle; #Pb0.05, chelerythrine v. control at each con-
centration of TP508.
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DNA fragmentation [32]. Cells were labeled with [3H]-thymidine for 4h before
the treatment. After the treatment, the cells were lysed and centrifuged to
separate the fragmented DNA and the intact DNA. [3H] in the supernatant and
the pellet was measured by scintillation counting, and the percentage of
apoptotic cells was determined by dividing the amount of fragmented DNAwith
the total DNA. In addition, cells treated with chelerythrine or tamoxifen were
examined by TUNEL staining using an In Situ Cell Death Detection Kit (Roche
Applied Science, Indianapolis, IN) in order to verify that DNA fragmentation
had occurred [33]. Cell viability was determined using an MTT assay kit
(Promega, Madison, WI).
Caspase-3 activity was assayed using a Caspase-3 Assay Kit (Sigma-
Aldrich, St. Louis, MO) following the manufacturer's instructions. Confluent
cultures were treated for 24h with 10μM chelerythrine or 10− 9M tamoxifen.
Lysates of these cultures were incubated with acetyl Asp-Glu-Val-Asp 7-amido-
4-methylcoumarin, a substrate of caspase-3, for 1h. At that time, fluorescence
was measured at excitation and emission wavelengths of 360 and 460nm,
respectively, to determine the amount of 7-amino-4-methylcoumarin (AMC)
produced. Results were normalized to cell number.
2.6. Role of nitric oxide
The universal NO synthase inhibitor L-NMMA (Sigma-Aldrich, St. Louis,
MO) was used to assess the effect of NO production on chondrocyte apoptosis
[34]. To determine the specific NO synthase subspecies that was involved,
inducible NO synthase (iNOS) inhibitor 1400W (Sigma-Aldrich, St. Louis, MO)
[35] and neuronal NO synthase (nNOS) inhibitor vinyl-L-NIO (Sigma-Aldrich,
St. Louis, MO) [36], as well as L-NAME (Sigma-Aldrich, St. Louis, MO), which
inhibits both iNOS and eNOS [37], were used together with TP508 to block NO
production.
2.7. Statistical analysis
All cell culture experiments were repeated at least twice. For each
experiment, there were six independent cultures for each variable. Statistical
significance was determined using ANOVA and post-hoc testing with
Bonferroni's modification of Student's t-test. The threshold of significance
was set as P-value b 0.05.
3. Results
3.1. Bcl-2/Bax
The ratio of Bcl-2 to Bax mRNAs varied with TP508 dose
and treatment time (Fig. 1A). At 1h, TP508 caused a dose-
dependent increase in Bcl-2 and a decrease in Bax expression.
By 3h of treatment, Bax levels increased and the ratio of
mRNAs for the two proteins was essentially 1. At 6 and 12h,
Bcl-2 mRNAs were relatively constant and independent of
TP508 treatment. At 6h, levels of Bax varied with dose but the
levels of Bcl-2 were constant up to 7μg/ml TP508. At 12h, there
was little evidence of Bax expression in control cultures but all
TP508 doses caused a comparable increase in Bax, resulting in a
Bcl-2/Bax ratio approximating 1. Changes in Bcl-2 and Bax
protein levels reflected the mRNA ratios. At 1h, there was a
62.9% increase in the Bcl-2/Bax protein ratio (Fig. 1B).
3.2. Protein kinase C activity
TP508 caused a dose-dependent increase in PKC activity in
female resting zone cells that was evident within 9min and
remained elevated over 6h (Fig. 1C). At 9min, the stimulatoryeffects were seen at concentrations of 7 and 14μg/ml TP508. By
90min, even the low dose of TP508 was effective.
3.3. Regulation of apoptosis
Chelerythrine caused a decrease in cell number (Fig. 2A) and
cell viability (Fig. 2B) in female rat chondrocytes, indicating
Table 1
The effect of TP508 on chelerythrine-induced DNA fragmentation of human
auricular chondrocytes
Control 10 μM chelerythrine
Control 3.74±0.95 8.01±1.32 a, b
7 μg/ml TP508 4.62±1.34 4.67±0.49
a pb0.05 against control group.
b pb0.05 against 0 μg/ml TP508 groups.
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chelerythrine on cell number and cell viability were partially
reversed by TP508 in a dose-dependent manner. Chelerythrine
also caused an increase in DNA fragmentation in female restingFig. 3. Effect of chelerythrine and tamoxifen on the number of TUNEL-labeled cel
growth plate chondrocyte cultures isolated from female rats. Cultures were treated w
presented are from one of at least two separate experiments, all of which had com
v. tamoxifen alone.zone chondrocytes (Fig. 2C) and human auricular chondrocytes
(Table 1), which was blocked by TP508 in a dose-dependent
manner. Similar effects on cell number, MTT activity and DNA
fragmentation were observed in male chondrocytes (data not
shown). TUNEL staining confirmed that chelerythrine induced
DNA fragmentation in rat chondrocytes (Fig. 3B) compared
with control cultures (Fig. 3A). TUNEL staining showed that
tamoxifen also induced DNA fragmentation (Fig. 3C), and the
two agents in combination increased the number of TUNEL-
labeled cells over the amount seen in response to either agent
alone (Fig. 3D). DNA fragmentation in the rat chondrocytes in
response to tamoxifen was comparable to that seen in cultures
treated with chelerythrine, and the effects of the two agents werels (A–D) and DNA fragmentation (E) of confluent resting zone costochondral
ith 10−9 M tamoxifen, 10 μM chelerythrine or their combination for 24 h. Data
parable results. ⁎Pb0.05, treatment v. 1.0; #Pb0.05, tamoxifen+chelerythrine
Table 2
The dose-dependent effect of Pi on DNA fragmentation
Pi concentration Percent fragmented Viability
17M. Zhong et al. / Biochimica et Biophysica Acta 1783 (2008) 12–22additive (Fig. 3E). No changes in caspase-3 activity were
detected as a function of chelerythrine, tamoxifen, or Pi treat-
ment (data not shown).Fig. 4. Effect of TP508 on tamoxifen and Pi-induced cell death of confluent
resting zone costochondral growth plate chondrocyte cultures isolated from
female rats. Cultures were treated with 10−9 M tamoxifen (A, B) or 7.5 mM Pi
(C) for 24 h in the presence or absence of 7 μg/ml TP508. Cell death was
measured using MTT assay to assess viability (A) and by DNA fragmentation
assay (B,C). Data are means±SEM for N=6 independent cultures. Data
presented are from one of at least two separate experiments, all of which had
comparable results. ⁎Pb0.05, treatment v. vehicle; #Pb0.05, tamoxifen alone
and tamoxifen+TP508 v. TP508 alone (A,B); #Pb0.05, Pi+TP508 v. Pi alone
(C); •Pb0.05, tamoxifen+TP508 v. tamoxifen alone (A).
(mM) DNA (%) (treatment/control)
0 4.67±0.63 1
2.5 8.42±1.08 a 0.85±0.04
5 9.91±1.11 a 0.84±0.04
7.5 16.06±0.10 a, b 0.72±0.03
a pb0.05 against control group.
b pb0.05 against 2.5 mM Pi group.TP508 reduced the effect of tamoxifen on chondrocyte
viability (Fig. 4A) and on DNA fragmentation (Fig. 4B). The
apoptogen Pi also induced a dose-dependent decrease in
chondrocyte viability and an increase in DNA fragmentation
(Table 2). TP508 reduced the effects of Pi on DNA fragmenta-
tion (Fig. 4C). In the tamoxifen data set shown, TP508 alone had
a small inhibitory effect onMTTactivity and a small stimulatory
effect on DNA fragmentation. This effect of TP508 on viability
was seen in four of six experiments, but the effect on DNA
fragmentation was only observed in three of ten experiments.
The Pi example is typical of experiments showing a lack of
TP508 effect on DNA fragmentation.
3.4. Role of nitric oxide
Chelerythrine (Fig. 5A), tamoxifen (Fig. 5B), and Pi
(Fig. 5C), all caused a dose-dependent increase in NO pro-
duction in rat resting zone chondrocytes. On a comparative
basis, chelerythrine was the most potent stimulator and Pi the
least potent. The effects of tamoxifen were bimodal with peak
stimulation at 10− 9M. TP508 significantly reduced chelerythr-
ine-dependent NO production in a dose-dependent manner
although levels remained greater than in control cultures even at
the highest concentration of peptide (Fig. 5D). TP508 blocked
the stimulatory effects of tamoxifen (Fig. 5E) and Pi (Fig. 5F).
When the rat cartilage cells were treated with chelerythrine
together with the NO synthase inhibitor L-NMMA, L-NMMA
blocked NO production induced by chelerythrine (Fig. 6A).
Moreover, L-NMMA also blocked loss of cell viability caused
by chelerythrine (Table 3). At least part of the NO produced in
response to chelerythrine was via an iNOS mechanism based on
the reduction in NO by the iNOS/eNOS inhibitor L-NAME
(Fig. 6B) and the iNOS inhibitor 1400W (Fig. 6C). TP508
reduced NO levels in control cultures to the same extent as
1400W but not to the same extent as L-NAME. TP508 and L-
NAME both reduced NO production induced by chelerythrine
but the peptide was less effective. In contrast, TP508 and
1400W had comparable inhibitory effects on NO production in
non-stimulated cultures and both had comparable inhibitory
effects on cultures stimulated with chelerythrine. The nNOS
inhibitor had no effect (Fig. 6D).
The stimulatory effect of chelerythrine on NO production by
rat resting zone chondrocytes was time-dependent; it was
evident at 90min and had maximal increases at 12h (Fig. 6E).
TP508 reduced NO levels in control cultures at 9 and 90min.
In addition, TP508 caused a greater than 90% reduction in
Fig. 5. Effect of TP508 on NO production in response to chelerythrine, tamoxifen and Pi by confluent resting zone costochondral growth plate chondrocyte cultures isolated from female rats. Cultures were treated with
0.1 to 10 μM chelerythrine (A), 10−11 to 10−9 M tamoxifen (B) or 2.5 to 7.5 mM Pi for 24 h (C). Alternatively, cultures were treated with 0.7 and 7 μg/ml TP508 in the presence or absence of 10 μM chelerythrine (D),
10−9 M tamoxifen (E) or 7.5 mM Pi (F) for 24 h. Data are means±SEM for N=6 independent cultures. Data presented are from one of at least two separate experiments, all of which had comparable results. ⁎Pb0.05,
treatment v. vehicle controls; #Pb0.05, 10−9 and 10−8 M tamoxifen v. 10−10 M tamoxifen (B); #Pb0.05, treatment v. control at each concentration of TP508 (D,E,F); •Pb0.05, 10 μm chelerythrine v. 0.1 and 1 μm
chelerythrine (A); •Pb0.05, 10−8 M tamoxifen v. 10−10 M tamoxifen (B).
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Fig. 6. Effect of NOS inhibitors on chelerythrine-induced NO production (A–D) and the time course of chelerythrine-induced NO production (E) of confluent resting
zone costochondral growth plate chondrocyte cultures isolated from female rats. Cultures were treated with 7 μg/ml TP508, 10 μM chelerythrine or their combination,
in the presence or absence of 1 mM L-NMMA (A), 50 μM L-NAME (B), 5 μM1400W (C) and 1 μMvinyl-L-NIO (D). Alternatively, cultures were treated with 7 μg/ml
TP508, 10 μM chelerythrine, or their combination for 9 to 1440 min (E). Data are means±SEM for N=6 independent cultures. Data presented are from one of at least
two separate experiments, all of which had comparable results. ⁎Pb0.05, treatment v. vehicle; #Pb0.05, inhibitor v. control groups for each treatment; •Pb0.05,
chelerythrine+TP508 v. chelerythrine alone.
19M. Zhong et al. / Biochimica et Biophysica Acta 1783 (2008) 12–22chelerythrine-induced NO production at all time points
examined. Moreover, the general NO inhibitor L-NMMA
reduced the effect of chelerythrine (Fig. 7A) and Pi (Fig. 7B)
on DNA fragmentation, indicating that the inhibitory effect of
chelerythrine on cell viability was mediated by NO and that
TP508 blocked this effect by reducing NO production.4. Discussion
In this study, we first established chelerythrine, tamoxifen
and inorganic phosphate as apoptosis inducers in rat growth zone
chondrocytes as indicated by increased DNA fragmentation,
TUNEL staining and decreased cell viability. Although other
Table 3
The effect of L-NMMA on chelerythrine-induced NO production
Chelerythrine (μM) NO production (nmol NO2
−/cell×10−5)
Control L-NMMA
0 0.79±0.11 0.92±0.07
0.1 3.02±0.19 a 0.82±0.16 b
1 3.78±0.59 a 1.92±0.40 a, b, c
10 9.28±0.29 a, d 3.33±0.84 a, b, c, d
a pb0.05 against 0 μM chelerythrine groups.
b pb0.05 against control groups.
c pb0.05 against 0.1 μM chelerythrine groups.
d pb0.05 against 1 μM chelerythrine groups.
Fig. 7. Effect of L-NMMA on chelerythrine (A) or Pi (B) induced apoptosis of
confluent resting zone costochondral growth plate chondrocyte cultures isolated
from female rats. Cultures were treated with 10 μMchelerythrine (A) or 7.5M Pi
(B) in the presence or absence of 7 μg/ml TP508 for 24 h. Data are means±SEM
for N=6 independent cultures. Data presented are from one of at least two
separate experiments, all of which had comparable results. ⁎Pb0.05, treatment
v. vehicle; #Pb0.05, apoptogen+L-NMMA v. apoptogen alone.
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DNA fragmentation assay we used is specific to apoptotic cells.
However, we did not observe an increase in caspase-3 activity
caused by these apoptosis inducers. It is possible that our
caspase-3 assay was not sensitive enough, or we had not found
the exact time when caspase-3 is activated. Alternatively, these
apoptotic pathways might be caspase-independent, as pre-
viously reported in other cases of chondrocyte apoptosis [38,39].
We demonstrated that TP508 blocks apoptosis induced by
chelerythrine and tamoxifen in resting zone chondrocytes. Both
of the apoptogens inhibit PKC in these cells [30,31]. Although
PKC activation has been associated with proliferation in many
cell types [18,19,40], TP508 does not increase proliferation in
resting zone chondrocytes, either as a function of cell number or
as a function of [3H]-thymidine incorporation [12]. We did not
specifically test whether TP508 blocked the decrease in PKC
caused by chelerythrine and tamoxifen; however, it is possible
that the ability of TP508 to increase PKC activity in resting zone
cells may play a role in its anti-apoptotic action.
Inorganic phosphate also induced apoptosis in the rat growth
plate chondrocytes, as has been noted by others examining
chick growth plate chondrocytes [7]. Interestingly, the effects of
Pi in the present study were on resting zone cells, which under
normal physiological conditions would not be exposed to high
concentrations of free phosphate typical of the hypertrophic
zone of the growth plate [41,42]. This supports the hypothesis
that regulation of Pi concentration in the extracellular matrix is
an important feature of growth plate development [7,43]. As
was seen with chelerythrine and tamoxifen, TP508 was able to
reduce Pi's effects on DNA fragmentation and MTT activity.
The sensitivity of the rat growth plate chondrocytes to
chelerythrine and Pi was not sex-specific. Both female and male
cells exhibited similar loss of viability and similar increases in
DNA fragmentation. Tamoxifen also induced apoptosis in cells
derived from both female and male rats, but there were
differences in sensitivity; tamoxifen's effect on male cells was
less than on female cells. Tamoxifen is used clinically to block
the effects of estrogen and has been reported to do so both by its
inhibitory effects on estrogen-dependent PKC signaling [31], as
well as by binding to estrogen receptors [44]. We have shown
that its ability to inhibit PKC in rat growth plate chondrocytes is
not sex-specific [31], but male chondrocytes possess fewer
estrogen receptors than female cells [45], which may account
for the difference in tamoxifen-dependent apoptosis. The factthat the effects of chelerythrine and tamoxifen were additive
regardless of the sex of the cells indicates that the two PKC
inhibitors worked via different mechanisms but the two
mechanisms were the same in both sexes.
Our results show that TP508′s anti-apoptotic effect also
works for human chondrocytes. Moreover, our results support
those of others using chick growth plate chondrocyte as a model
that Pi induces apoptosis by an NO-mediated pathway [15].
Here, we show that NO production was also increased in
cultures treated with chelerythrine and tamoxifen. Treatment of
chelerythrine-stimulated cells with the general NO synthase
inhibitor L-NMMA reduced the apoptotic effects, indicating that
NO production also mediated induction of apoptosis in the
resting zone cells. Importantly, TP508 was able to reduce NO
production caused by all three agents that induced apoptosis in
these cells. In addition, TP508 was able to reduce the increase in
DNA fragmentation and the decrease in MTT activity caused by
these three apoptogens, suggesting that its anti-apoptotic effect
was via inhibition of NO production.
Our results indicate that TP508 reduces NO that is produced
by iNOS. Specific inhibition of iNOS with 1400W reduced
chelerythrine-dependent NO production to a similar extent as
TP508. L-NAME, which inhibits both iNOS and eNOS, was
21M. Zhong et al. / Biochimica et Biophysica Acta 1783 (2008) 12–22more effective than 1400W, suggesting the possibility that
eNOS might also play a role. eNOS is present in chick sternal
chondrocytes that are undergoing hypertrophy [46] and others
have reported eNOS in rat osteoblasts [47], suggesting that rat
chondrocytes may also possess this form of the enzyme.
Osteoblasts from eNOS knockout mice exhibit reduced alkaline
phosphatase [48] and inhibition of eNOS with L-NAME reduces
alkaline phosphatase in the chick cartilage cells [15]. We have
previously noted that TP508 reduces alkaline phosphatase
activity in rat growth plate chondrocytes [12], further support-
ing a role for eNOS. Although nNOS has also been found in
chondrocytes [15], the nNOS inhibitor had no effect, indicating
that nNOS was not involved.
These results indicate that TP508, besides its effect on
retaining the rat resting zone chondrocyte phenotype, is also
able to directly protect it from undergoing apoptosis. Interest-
ingly, the effect of TP508 on PKC activation and NO inhibition
was rapid and sustained over 12 h, indicating nongenomic
signaling and suggesting downstream genomic effects. Expres-
sion of Bcl-2 and Bax mRNA and protein was regulated by
TP508 in a dose and time-dependent manner, with the effects
occurring within 1 h. Upregulation of Bcl-2 and down-
regulation of Bax are consistent with the hypothesis that
TP508 reduces apoptosis through the Bcl-2/Bax mechanism
early in the response pathway. Our results suggest that the main
effect of TP508 is to expand the reservoir of chondrocytes that
serve to populate the template for endochondral bone formation.
This study also confirmed that NO produced by iNOS is a
crucial mediator in chondrocyte apoptosis, and suggests a role
for eNOS in the apoptotic mechanism.
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